Skip to main content
Premium Trial:

Request an Annual Quote

Six RNAi-Related Patent Application s Published by the USPTO

Premium

Title: Compositions and Methods for Gene Silencing

Number: 20050229272

Filed: April 19, 2005 PCT Filed: Jan. 2, 2001

Lead Inventor: Monica Driscoll, Rutgers University

According to the patent application's abstract, "DNA constructs are provided for disrupting gene expression in targeted organisms."


Title: Method for Producing Non-Human Mammal RNAi Phenotype Using Papilloma Virus Vector

Number: 20050229266

Filed: Jan. 14, 2005

Lead Inventor: Motoya Katsuki, Mitsubishi Chemical

According to the patent application's abstract, the invention "is [designed] to improve a method for introducing dsRNA, so as to improve the efficiency of obtaining mammals such as mice having an RNAi phenotype. The … invention provides a method for producing a non-human mammal wherein the function of a target gene is suppressed, which comprises introducing into cells a papilloma virus vector into which the target gene has been incorporated."


Title: Amplifying Interfering RNA Expression and Effects

Number: 20050227940

Filed: Jan. 24, 2005

Lead Inventor: John Rossi, City of Hope

The patent application, its abstract states, covers "methods for amplifying expression of interfering RNA, and preferably siRNA or shRNA, using [an] RNAi (si/shRNA)-expressing concatamer. The methods are useful for modulating, including down-regulating and/or inhibiting, expression of a target gene in cells, including mammalian cells."


Title: RNA Interference-Mediated Inhibition of TGF-Beta and TGF-Beta Receptor Gene Expression Using Short Interfering Nucleic Acid

Number: 20050227936

Filed: Aug. 20, 2004

Lead Inventor: James McSwiggen, Sirna Therapeutics

"This invention relates to compounds, compositions, and methods useful for modulating transforming growth factor beta (TGF-beta) and/or transforming growth factor beta receptor (TGF-betaR) gene expression using short interfering nucleic acid molecules," the patent application's abstract states. "This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of TGF-beta and/or TGF-betaR gene expression and/or activity by RNA interference using small nucleic acid molecules. In particular, the … invention features small nucleic acid molecules, such as short interfering nucleic acid, short interfering RNA, double-stranded RNA, microRNA, and short hairpin RNA molecules and methods used to modulate the expression of TGF-beta and/or TGF-betaR genes."


Title: RNA Interference-Mediated Inhibition of TNF and TNF Receptor Gene Expression Using Short Interfering Nucleic Acid

Number: 20050227935

Filed: Aug. 20, 2004

Lead Inventor: James McSwiggen, Sirna Therapeutics

"This invention relates to compounds, compositions, and methods useful for modulating tumor necrosis factor and/or tumor necrosis factor receptor gene expression using short interfering nucleic acid molecules," the patent application's abstract states. "This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of tumor necrosis factor and/or tumor necrosis factor receptor gene expression and/or activity by RNA interference using small nucleic acid molecules. In particular, the … invention features small nucleic acid molecules, such as short interfering nucleic acid, short interfering RNA, double-stranded RNA, microRNA, and short hairpin RNA molecules and methods used to modulate the expression of tumor necrosis factor and/or tumor necrosis factor receptor genes."


Title: Sequence-Specific Inhibition of Small RNA Function

Number: 20050227256

Filed: Nov. 26, 2004

Lead Inventor: Gyorgy Hutvagner, University of Massachusetts

"The … invention relates to the discovery of a method for inhibiting RNA silencing in a target sequence-specific manner," the patent application's abstract states. "RNA silencing requires a set of conserved cellular factors to suppress expression of gene-encoded polypeptide. The invention provides compositions for sequence-specific inactivation of the RISC component of the RNA silencing pathway, and methods of use thereof. The RISC inactivators of the present invention enable a variety of methods for identifying and characterizing miRNAs and siRNAs, RISC-associated factors, and agents capable of modulating RNA silencing. Therapeutic methods and compositions incorporating RISC inactivators and therapeutic agents identified through use of RISC inactivators are also featured."

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.